Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV.
Ferrara M, Cusato J, Salvador E, Trentalange A, Alcantarini C, Trunfio M, Cannizzo ES, Bono V, Nozza S, De Nicolò A, Ianniello A, De Vivo E, D'Avolio A, Di Perri G, Bonora S, Marchetti G, Calcagno A. Ferrara M, et al. Among authors: nozza s. Br J Clin Pharmacol. 2023 Mar;89(3):1020-1026. doi: 10.1111/bcp.15538. Epub 2022 Oct 11. Br J Clin Pharmacol. 2023. PMID: 36115063 Free article.
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism.
Siccardi M, D'Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, Moss D, Kwan WS, Castagna A, Lazzarin A, Calcagno A, Bonora S, Back D, Di Perri G, Owen A. Siccardi M, et al. Among authors: nozza s. Pharmacogenet Genomics. 2010 Dec;20(12):759-65. doi: 10.1097/FPC.0b013e3283402efb. Pharmacogenet Genomics. 2010. PMID: 21217360 Clinical Trial.
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.
Calcagno A, Nozza S, Bonora S, Castagna A, Gonzalez de Requena D, D'Avolio A, Lazzarin A, Di Perri G. Calcagno A, et al. Among authors: nozza s. J Antimicrob Chemother. 2011 Aug;66(8):1932-4. doi: 10.1093/jac/dkr219. Epub 2011 Jun 4. J Antimicrob Chemother. 2011. PMID: 21642649 No abstract available.
Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients.
Calcagno A, Nozza S, Gonzalez de Requena D, Galli A, D'Avolio A, Simiele M, Chiappetta S, Di Perri G, Lazzarin A, Bonora S. Calcagno A, et al. Among authors: nozza s. J Antimicrob Chemother. 2013 Jul;68(7):1686-8. doi: 10.1093/jac/dkt074. Epub 2013 Mar 14. J Antimicrob Chemother. 2013. PMID: 23493315 No abstract available.
Highlights on HIV eradication in 2013.
Monforte Ad, Svicher V, Nozza S, Lazzarin A, Marchetti G, Perno CF. Monforte Ad, et al. Among authors: nozza s. AIDS. 2014 Jan 2;28(1):1-7. doi: 10.1097/01.aids.0000433241.78739.79. AIDS. 2014. PMID: 23939240 Free article. No abstract available.
Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodology.
Marcotullio S, Ammassari A, Andreoni M, Antinori A, Bonora S, d'Arminio Monforte A, Di Perri G, Galli M, Gervasoni C, Iardino R, Ippolito G, Lo Caputo S, Nozza S, Perno CF, Rizzardini G, Lazzarin A. Marcotullio S, et al. Among authors: nozza s. New Microbiol. 2014 Apr;37(2):163-75. Epub 2014 Apr 1. New Microbiol. 2014. PMID: 24858643 Free article.
Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting.
Gianotti N, Cozzi-Lepri A, Antinori A, Di Biagio A, Moioli MC, Nozza S, Cingolani A, De Luca A, Madeddu G, Bonora S, Ceccherini-Silberstein F, Monforte Ad; ICONA Foundation Study. Gianotti N, et al. Among authors: nozza s. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19799. doi: 10.7448/IAS.17.4.19799. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397543 Free PMC article.
247 results